Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate
Scribe Therapeutics (NASDAQ:SCTX) reported quarterly losses of $(2.62) per share which missed the analyst consensus estimate of $(1.05) by 149.52 percent. The company reported quarterly sales of $1.918 million which
Scribe Therapeutics lost more money per share than experts thought it would, and made less sales than expected. When a company misses on both money lost and sales, it means the business isn't growing as fast as people hoped, so it's worth watching to see what happens next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.